238 related articles for article (PubMed ID: 15466278)
1. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk.
Cournoyer D; Toffelmire EB; Wells GA; Barber DL; Barrett BJ; Delage R; Forrest DL; Gagnon RF; Harvey EA; Laneuville P; Patterson BJ; Poon MC; Posen GA; Messner HA;
J Am Soc Nephrol; 2004 Oct; 15(10):2728-34. PubMed ID: 15466278
[TBL] [Abstract][Full Text] [Related]
2. Pure red-cell aplasia and epoetin therapy.
Bennett CL; Luminari S; Nissenson AR; Tallman MS; Klinge SA; McWilliams N; McKoy JM; Kim B; Lyons EA; Trifilio SM; Raisch DW; Evens AM; Kuzel TM; Schumock GT; Belknap SM; Locatelli F; Rossert J; Casadevall N
N Engl J Med; 2004 Sep; 351(14):1403-8. PubMed ID: 15459301
[TBL] [Abstract][Full Text] [Related]
3. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).
Macdougall IC; Casadevall N; Locatelli F; Combe C; London GM; Di Paolo S; Kribben A; Fliser D; Messner H; McNeil J; Stevens P; Santoro A; De Francisco AL; Percheson P; Potamianou A; Foucher A; Fife D; Mérit V; Vercammen E;
Nephrol Dial Transplant; 2015 Mar; 30(3):451-60. PubMed ID: 25239637
[TBL] [Abstract][Full Text] [Related]
4. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
Macdougall IC
Curr Med Res Opin; 2004 Jan; 20(1):83-6. PubMed ID: 14741076
[TBL] [Abstract][Full Text] [Related]
5. [Pure red cell aplasia in erythropoietin therapy in patients with kidney failure].
Opatrný K
Cas Lek Cesk; 2003; 142(12):741-5. PubMed ID: 14746223
[TBL] [Abstract][Full Text] [Related]
6. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin.
Shimizu H; Saitoh T; Ota F; Jimbo T; Tsukada Y; Murakami H; Nojima Y
Acta Haematol; 2011; 126(2):114-8. PubMed ID: 21654161
[TBL] [Abstract][Full Text] [Related]
7. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.
Boven K; Stryker S; Knight J; Thomas A; van Regenmortel M; Kemeny DM; Power D; Rossert J; Casadevall N
Kidney Int; 2005 Jun; 67(6):2346-53. PubMed ID: 15882278
[TBL] [Abstract][Full Text] [Related]
8. Eprex (recombinant human erythropoietin alfa) and pure red cell aplasia--recommendations for administration to patients with CRF.
S Afr Med J; 2003 Nov; 93(11):839. PubMed ID: 14677505
[No Abstract] [Full Text] [Related]
9. Pure red cell aplasia secondary to treatment with erythropoietin.
Locatelli F; Del Vecchio L
J Nephrol; 2003; 16(4):461-6. PubMed ID: 14696747
[TBL] [Abstract][Full Text] [Related]
10. Epoetin-associated pure red cell aplasia: past, present, and future considerations.
McKoy JM; Stonecash RE; Cournoyer D; Rossert J; Nissenson AR; Raisch DW; Casadevall N; Bennett CL
Transfusion; 2008 Aug; 48(8):1754-62. PubMed ID: 18482185
[TBL] [Abstract][Full Text] [Related]
11. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery.
Boven K; Knight J; Bader F; Rossert J; Eckardt KU; Casadevall N
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii33-40. PubMed ID: 15824129
[TBL] [Abstract][Full Text] [Related]
12. Antibody-mediated pure red-cell aplasia (PRCA): the Spanish experience.
Carracedo J; Madueño JA; Ramirez R; Martin-Malo A; de Francisco AL; Aljama P;
J Nephrol; 2005; 18(4):382-7. PubMed ID: 16245241
[TBL] [Abstract][Full Text] [Related]
13. Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure.
Lim LC
Hematology; 2005 Jun; 10(3):255-9. PubMed ID: 16019474
[TBL] [Abstract][Full Text] [Related]
14. Importance of biologic follow-ons: experience with EPO.
Casadevall N; Rossert J
Best Pract Res Clin Haematol; 2005; 18(3):381-7. PubMed ID: 15792912
[TBL] [Abstract][Full Text] [Related]
15. Recovery of pure red-cell aplasia secondary to antierythropoietin antibodies after cessation of recombinant human erythropoietin.
Panchapakesan U; Austin SK; Shafransky A; Lawrence JA; Savdie E
Intern Med J; 2003; 33(9-10):468-71. PubMed ID: 14511202
[TBL] [Abstract][Full Text] [Related]
16. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
Macdougall IC
Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv9-15. PubMed ID: 15827058
[TBL] [Abstract][Full Text] [Related]
17. Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia.
Fijal B; Ricci D; Vercammen E; Palmer PA; Fotiou F; Fife D; Lindholm A; Broderick E; Francke S; Wu X; Colaianne J; Cohen N
Pharmacogenomics; 2008 Feb; 9(2):157-67. PubMed ID: 18370845
[TBL] [Abstract][Full Text] [Related]
18. Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group.
Evens AM; Bennett CL; Luminari S
Best Pract Res Clin Haematol; 2005; 18(3):481-9. PubMed ID: 15792923
[TBL] [Abstract][Full Text] [Related]
19. Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone.
Andrade J; Taylor PA; Love JM; Levin A
Nephrol Dial Transplant; 2005 Nov; 20(11):2548-51. PubMed ID: 16046510
[TBL] [Abstract][Full Text] [Related]
20. Pure red-cell aplasia "epidemic"--mystery completely revealed?
Locatelli F; Del Vecchio L; Pozzoni P
Perit Dial Int; 2007 Jun; 27 Suppl 2():S303-7. PubMed ID: 17556324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
